Lisata TherapeuticsLSTA
Recorded

Lisata Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration24 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

All right. So good morning, everyone, and welcome to the Jefferies 2026 Global Healthcare Conference. It is my pleasure to introduce you now Josh Lehrer, CEO of Marea Therapeutics. Just a reminder that the presentation will be 20 minutes long, follow up with a five minutes Q&A.

Josh LehrerCEO

Thank you. Thanks, and thanks to the Jefferies team for having us here.

Josh LehrerCEO

Can you guys see slides? Okay, great. I'll be making forward-looking statements today. Marea recently completed a merger with Lisata Therapeutics with a concurrent PIPE financing that has financed us through middle of 2028 and through a number of important milestones for our programs. So Marea, we are focused on developing two clinical stage molecules. Both are founded on strong human genetics and have the potential to transform the treatment of diseases for important indications where existing therapies can deliver efficacy, but both come with limitations, and we think we can improve on patient outcomes. So our lead program is MAR001. This is a first-in-class antibody to ANGPTL4, and MAR005, its half-life extended variant, which will become our phase III molecule. And we're developing this program to treat patients suffering from severe hypertriglyceridemia.

Josh LehrerCEO

sHTG affects 3 million individuals in the U.S., and these patients are really at dual risk from both cardiovascular disease as well as acute pancreatitis, which is a devastating clinical outcome. ApoC-III inhibitors, of which one is now approved, have demonstrated that potent lowering of triglycerides can drastically reduce these adverse outcomes and reduce pancreatitis events. But this efficacy does come at a cost, and that cost is worse glucose control, which is a significant issue because the majority of these patients have type 2 diabetes, many poorly controlled. Our phase IIb data, which we recently presented, and I'll go over here, demonstrates a profile that's different. It's very encouraging in indicating that we may have a molecule that can match the ApoC-III inhibitors on efficacy, on triglyceride lowering, ultimately pancreatitis event reduction, but have a clean metabolic profile on glucose.

Josh LehrerCEO

And we think that's important in a large number of patients and a commercial opportunity that's projected to grow to $10 billion or more in the U.S. Our second program is MAR002. This is the first long-acting direct growth hormone antagonist that's being developed for acromegaly. Acromegaly is a severe endocrine disease with significant morbidity and mortality in patients who are untreated and not treated to goal, to achieve full biochemical control and normalization of growth hormone levels as assessed by IGF-1. Most patients remain uncontrolled despite first-line therapy with somatostatin receptor ligands. We know that the most effective class of drugs in this disease is direct growth hormone blockade, but there's only one available therapy in this class, and it has significant limitations, including daily dosing and safety tolerability issues for patients.

Josh LehrerCEO

We've designed what we think can become an optimal direct growth hormone antagonist with a significantly improved profile in terms of dosing and safety and tolerability. We have healthy volunteer phase I data that goes a long way towards establishing this profile. I'll review that data today. We think that this can really transform the treatment and become the mainstay of therapy for most patients, getting most patients to goal. This is projected to grow to become a large U.S. opportunity. It's a $1.4 billion total in acromegaly, but we think that an optimal direct growth hormone antagonist alone could be in excess of that opportunity. Where the programs stand now, leading towards a number of milestones in 2027. For our lead program in sHTG, we have read out a phase IIb study, and that's the data I'll be reviewing today.

Josh LehrerCEO

We are now screening patients in a second part to that study, which will add additional numbers of patients who have severe hypertriglyceridemia. That dataset will be available by the end of next year. For our phase III candidate, MAR005, this is an improved half-life extended variant of MAR001. This is currently in an ongoing PK/PD bridging study for which we have FDA agreement, and the next step for that study is dose selection data, which we'll be disclosing around the middle of next year, and then moving towards phase III start before the end of next year. For MAR002, we've completed, as I mentioned, a healthy volunteer phase I study, and even though this is a phase I study, the data is very informative on the profile of the molecule with proof of mechanism data. We'll review that today. We started dosing patients in a phase II proof of concept study in September, and that study will read out with interim data in the middle of the year, complete data by the end of the year, and then we plan to move quickly towards phase III initiation in the first half of 2028.

Josh LehrerCEO

First, sHTG, and this is the need. There are 3 million total patients in the United States. About a million of these patients are at significant risk of pancreatitis events, many with recurrent pancreatitis. The main thing to know here is that these episodes carry really significant morbidity and mortality, really on the level of myocardial infarction. The difference being that until very recently, there were no therapies that had ever demonstrated clinical benefit for these patients in reducing these events and these adverse outcomes.

Josh LehrerCEO

The other point is that these patients are really being co-managed by their cardiologist, endocrinologist, and lipidologist, not just for the pancreatitis risk, but also in most cases for diagnosed type 2 diabetes, in many cases difficult to control diabetes, and also established coronary disease, as well as fatty liver. Aside from the patient impact, this is an expensive disease to take care of with standard of care therapies that were really inadequate. ApoC-III inhibitors, a new class of therapies, one is now approved, the other from Arrowhead has phase III data, and this really stands to transform treatment of this disease by delivering a step change in efficacy. By dramatically lowering triglyceride over what standard of care is able to achieve, most patients can be brought down below the risk threshold.

Josh LehrerCEO

Pancreatitis events were really significantly cut down, and we don't see hazard ratios like 0.15 very often in clinical trials these days, but we have with these drugs. That's what's driving projections of really significant opportunity, commercial opportunity, as well as patient impact. But this efficacy does come at a cost. What's seen here is the very consistent lowering of triglycerides across the two most advanced ApoC-III inhibitors, delivering triglyceride reductions in the range of 60%-80% in terms of change from baseline. But what's also consistent is a worsening in glucose control, and that's seen across trials in diabetic patients, an increase of approximately 0.3 points in hemoglobin A1C. That's seen consistently. This has consequence in some patients. We know that in the experience with plozasiran, dysglycemia was the leading cause of adverse events, and in the open-label extension, also the leading cause of treatment discontinuations.

Josh LehrerCEO

Why do we think that our target and our molecule can be different? We target a different protein, ANGPTL4, compared to ApoC-III, and really the main difference is where these two different proteins act and where the triglycerides are being disposed of. With ANGPTL4, this protein is a very potent inhibitor of triglyceride metabolism in adipose tissue. It shuts down lipoprotein lipase in adipose tissue. MAR001, by inhibiting ANGPTL4, is leading to triglyceride disposal in the adipose tissue, really putting fat back where it belongs, and there's no metabolic penalty to that. In contrast, ApoC-III has a number of different functions, but predominantly leads to uptake of triglyceride-rich lipoproteins in the liver and disposal of triglycerides in the liver. That's thought to lead to these metabolic signals, really as an on-mechanism effect, by having the potential to lead to deposition of ectopic fat in the liver.

Josh LehrerCEO

One of the ApoC-III inhibitors has a clear liver fat signal. Also to substrate switching, so preference in the liver for utilizing fatty acids over glucose and a risk of hyperglycemia. The human genetics actually predict this as well, so that's another difference. People who are missing this gene for ANGPTL4 actually have benefits in terms of reduced risk of diabetes and better insulin sensitivity. With ApoC-III, it's actually just the opposite, and that predicts the risk that's seen with the pharmacology and with the molecules that have been tested in the clinic. We designed a study to test whether MAR001 can actually deliver on a different profile. The study we designed is the TYDAL-TIMI 78 study, phase IIb study. We tested MAR001 in 235 patients across three active arms and placebo, dosed monthly.

Josh LehrerCEO

We treated patients for 24 weeks, and about half of these patients were diabetic, so very much informative on the metabolic profile. We looked at a wide range of triglyceride levels from 150 up to 880, so a subset of these patients had severe elevations in triglycerides and were sHTG patients. What we saw was a dose-dependent lowering of triglycerides through 12 weeks maintained to 24 weeks. At the high dose, we saw about 40% decrease in triglycerides from baseline. This was presented at AHA, and there's a QR code here for New England Journal publication for this data as well. What was really new was what we learned when we looked at subgroups, and when we looked at the effect of MAR001 in patients with more severe triglyceride elevations, and that's what's shown here.

Josh LehrerCEO

This is data from the middle and high dose that were pooled and compared to placebo, and what we saw was a scaled efficacy increasing from about 40% to 50% in patients with triglycerides over 300, and then to over 70% in patients with triglycerides over 500. This was the subgroup that had severe elevations. These are the patients we will be treating going forward. The caveat is that this was a subgroup. This study was not designed as a pure sHTG study, but what was very encouraging is when we looked at individual patient data, which is shown on the right, we saw that the effects were remarkably consistent. Every patient in the middle and high dose group achieved between a 60% to 80% reduction in triglycerides.

Josh LehrerCEO

When we look at that really side to side compared to the ApoC-III inhibitors, what we see is in these severe patients, triglyceride lowering that is very much comparable, and we know that triglyceride lowering accurately predicts subsequent reduction in pancreatitis events. So, potential to deliver the same kind of transformative efficacy that has been seen with ApoC-III inhibitors for these patients, but the glucose is different. You can see that in contrast to the 0.3 point increase in diabetic patients, that is seen really across the board, and that is despite active medical management in these trials with anti-diabetic therapies. We see no hint of a signal on glucose, actually a numeric reduction compared to placebo, and we have also seen no hint of any liver signals or liver fat with this molecule as well.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day